Current and historical daily PE Ratio for UCB (
LTS:0NZT
) from 2009 to May 21 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. UCB stock (LTS:0NZT) PE ratio as of May 21 2024 is 72.05.
More Details
UCB SA (LTS:0NZT) PE Ratio (TTM) Chart
UCB SA (LTS:0NZT) PE Ratio (TTM) Historical Data
View and export this data going back to 2009. Start your Free Trial
Total 1256
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| UCB PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-21 | 71.8 | 2024-03-14 | 60.9 |
| 2024-05-20 | 71.8 | 2024-03-13 | 61.2 |
| 2024-05-17 | 70.6 | 2024-03-12 | 61.6 |
| 2024-05-16 | 69.0 | 2024-03-11 | 61.6 |
| 2024-05-15 | 69.7 | 2024-03-08 | 62.5 |
| 2024-05-14 | 68.2 | 2024-03-07 | 62.0 |
| 2024-05-13 | 69.0 | 2024-03-06 | 62.0 |
| 2024-05-10 | 70.0 | 2024-03-05 | 60.4 |
| 2024-05-09 | 67.4 | 2024-03-04 | 61.4 |
| 2024-05-08 | 68.8 | 2024-03-01 | 61.9 |
| 2024-05-07 | 68.0 | 2024-02-29 | 60.3 |
| 2024-05-03 | 68.8 | 2024-02-28 | 59.6 |
| 2024-05-02 | 69.2 | 2024-02-27 | 55.1 |
| 2024-05-01 | 70.9 | 2024-02-26 | 55.0 |
| 2024-04-30 | 70.9 | 2024-02-23 | 54.9 |
| 2024-04-29 | 70.2 | 2024-02-22 | 54.4 |
| 2024-04-26 | 70.9 | 2024-02-21 | 53.5 |
| 2024-04-25 | 70.7 | 2024-02-20 | 54.2 |
| 2024-04-24 | 68.7 | 2024-02-19 | 54.3 |
| 2024-04-23 | 69.5 | 2024-02-16 | 54.0 |
| 2024-04-22 | 69.9 | 2024-02-15 | 53.6 |
| 2024-04-19 | 69.0 | 2024-02-14 | 53.4 |
| 2024-04-18 | 68.2 | 2024-02-13 | 53.0 |
| 2024-04-17 | 68.0 | 2024-02-12 | 53.8 |
| 2024-04-16 | 68.0 | 2024-02-09 | 53.0 |
| 2024-04-15 | 67.4 | 2024-02-08 | 51.1 |
| 2024-04-12 | 68.7 | 2024-02-07 | 50.5 |
| 2024-04-11 | 65.9 | 2024-02-06 | 49.4 |
| 2024-04-10 | 65.4 | 2024-02-05 | 48.8 |
| 2024-04-09 | 64.9 | 2024-02-02 | 49.1 |
| 2024-04-08 | 65.3 | 2024-02-01 | 49.2 |
| 2024-04-05 | 65.1 | 2024-01-31 | 49.7 |
| 2024-04-04 | 66.1 | 2024-01-30 | 48.9 |
| 2024-04-03 | 65.1 | 2024-01-29 | 48.7 |
| 2024-04-02 | 65.0 | 2024-01-26 | 49.6 |
| 2024-03-28 | 64.8 | 2024-01-25 | 48.7 |
| 2024-03-27 | 64.8 | 2024-01-24 | 49.4 |
| 2024-03-26 | 65.0 | 2024-01-23 | 48.3 |
| 2024-03-25 | 65.6 | 2024-01-22 | 48.0 |
| 2024-03-22 | 64.6 | 2024-01-19 | 46.7 |
| 2024-03-21 | 63.3 | 2024-01-18 | 46.6 |
| 2024-03-20 | 61.1 | 2024-01-17 | 46.9 |
| 2024-03-19 | 61.5 | 2024-01-16 | 47.4 |
| 2024-03-18 | 60.8 | 2024-01-15 | 47.4 |
| 2024-03-15 | 59.3 | 2024-01-12 | 47.8 |
UCB SA (LTS:0NZT) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
UCB SA
NAICS : 325412
ISIN : BE0003739530
Share Class Description:
LTS:0NZT: Ordinary SharesCompare
Compare
Traded in other countries / regions
UCB.Belgium0NZT.UKUCBJY.USAUNC.GermanyUCB.AustriaUCB.Mexico IPO Date
2009-10-07Description
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers